Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.40

+5.5%

Nov 11 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (184)	1/10/2003 11:07:54 AM
From: Jibacoa	Read Replies (1) of 3722

BTRN Is up 23.26% on volume of 165K Its AlloMune System allows incompatible organ transplants, human or animal. The Eligix Cell Separation System (to try to purify bone marrow before transplant) is already available in Europe and its MEDI-507, (a humanized monoclonal antibody that may be effective in treating T cell-mediated diseases) may be approved to treat psoriasis. Insiders hold 23% and institutions that hold 50% of the shares reportedly have done some buying lately in spite of the company's precariously looking financial condition.(At the present burn rate BTRN has enough cash for almost 2Q) siliconinvestor.com The stock has been forming a pretty good base since October and although still highly speculative, the R/R at this point doesn't look too bad.<g>. siliconinvestor.com (Yahoo lists analyst's 1yr. target for BTRN at 13 and I would be satisfied with somewhat less than half, like last year's March 28 aound 5.38<g>)(That would only be a 975% gain from present levels.<g>) siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next